iOncologi, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor-targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing immunotherapies for solid tumors. The acquisition aligns with iOncologi’s broader strategy to expand its therapeutic pipeline, leverage RNA-based immunotherapies, and drive innovation in oncology. As ...